BCEL Live signals | Maximize Profits with Getagraph.com

BUY 114139 min ago

@ $0.286

Issued: 14 Feb 2024 @ 12:10

Return: -68.46%

Previous signal: Feb 13 - 09:38

Previous signal: Sell

Return: 16.83 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 15:49):

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types...

Stats
Today's Volume	42 299.00
Average Volume	564 453
Market Cap	3.58M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $0 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.00300 (3.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Orwin John A	Buy	1	Series A Junior Preferred Stock
2024-04-01	Serafini Tito	Sell	20 788	Class A Common Stock
2023-09-01	Orwin John A	Sell	22 951	Class A Common Stock
2023-09-01	Serafini Tito	Sell	8 393	Class A Common Stock
2023-09-01	Courtney Phillips	Sell	7 061	Class A Common Stock

INSIDER POWER
26.25
Last 95 transactions
Buy: 4 455 146 \| Sell: 2 042 595

Atreca Inc Correlation

10 Most Positive Correlations
GETVV	0.975
ENG	0.934
KZR	0.92
DRCT	0.918
CTMX	0.917
PSTX	0.916
JAN	0.914
ALLK	0.911
DAWN	0.909
CKPT	0.908

10 Most Negative Correlations
BNIXU	-0.916
STAY	-0.907
PT	-0.899
NVCN	-0.894
OPRA	-0.893
DSPG	-0.893
SGEN	-0.886
CCRC	-0.879
XLNX	-0.879
LFMD	-0.879

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Atreca Inc Financials

Annual	2022
Revenue:	$770 000
Gross Profit:	$-6.31M (-819.61 %)
EPS:	$-2.35

FY	2022
Revenue:	$770 000
Gross Profit:	$-6.31M (-819.61 %)
EPS:	$-2.35

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.95

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.70

Financial Reports:

No articles found.

Atreca Inc

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.